Free Trial
NASDAQ:SOPH

SOPHiA GENETICS Q2 2025 Earnings Report

SOPHiA GENETICS logo
$3.67 +0.11 (+3.09%)
As of 01:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SOPHiA GENETICS EPS Results

Actual EPS
N/A
Consensus EPS
-$0.25
Beat/Miss
N/A
One Year Ago EPS
N/A

SOPHiA GENETICS Revenue Results

Actual Revenue
N/A
Expected Revenue
$17.49 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

SOPHiA GENETICS Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
12:00AM ET

Conference Call Resources

SOPHiA GENETICS Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More SOPHiA GENETICS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SOPHiA GENETICS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SOPHiA GENETICS and other key companies, straight to your email.

About SOPHiA GENETICS

SOPHiA GENETICS (NASDAQ:SOPH) is a data-driven medicine company that leverages artificial intelligence and advanced analytics to enable healthcare institutions and researchers to make more informed decisions in patient care. Founded in 2011 and headquartered in Boston, Massachusetts, with key operations in Geneva, Switzerland, SOPHiA GENETICS has established itself as a pioneer in the field of genomic and radiomic data interpretation. The company’s mission is to democratize data-driven medicine by providing scalable, cloud-based solutions that address critical challenges in diagnostics and treatment planning.

The core offering of SOPHiA GENETICS is its SOPHiA DDM™ platform, which integrates next-generation sequencing (NGS) data analysis, radiomics, and digital pathology workflows. By harmonizing multimodal biomedical data, the platform delivers standardized, reproducible insights that support the detection of genetic variants, the assessment of tumor phenotypes, and the characterization of rare diseases. SOPHiA DDM™ is designed to be vendor-agnostic, enabling laboratories to seamlessly incorporate diverse sequencing technologies and imaging modalities into their diagnostic pipelines.

SOPHiA GENETICS serves a wide range of customers, including clinical laboratories, hospitals, biopharmaceutical companies, and academic research centers across North America, Europe, Asia, and Latin America. The company’s cloud-based infrastructure facilitates secure data sharing and collaboration among healthcare professionals, accelerating research programs and clinical trials. To support local needs, SOPHiA GENETICS maintains regional offices and partnerships, ensuring compliance with evolving regulatory requirements and data privacy standards.

Under the leadership of co-founder and Chief Executive Officer Jurgi Camblong, SOPHiA GENETICS has pursued strategic partnerships with leading academic institutions, diagnostic companies, and pharmaceutical firms. The management team combines expertise in genomics, bioinformatics, and clinical development to drive ongoing innovation in artificial intelligence applications. Through continuous platform enhancements and collaborations, SOPHiA GENETICS is committed to expanding the adoption of data-driven medicine and improving patient outcomes worldwide.

View SOPHiA GENETICS Profile

More Earnings Resources from MarketBeat